The Vascular Venture Research Group was established at the end of 2017 as a sub-unit of VV. The goal of VRG is to conduct research and development according international standards in the field of toxins and their artificial derivatives effective in biological systems. The ultimate goal of the R&D at VRG is, of course, is to discover toxin derivatives effective in-vitro and in small animal models to be interested by larger market players for therapeutic purposes.
The base of research and development of the Vascular Research Group, a 200 sqm laboratory equipped with state-of-the-art technology is located on the campus at 15 Herman Ottó út in Budapest, with all new devices, optimally selected according to the research goals.
The researchers of the Vascular Research Group were selected based on international research experience and outstanding achievements. They have worked for years at the most prestigious institutes, such as the National Institutes of Health, USA, Fred Hutchinson Cancer Research Center, Karolinska Institute, etc. The two subunits of the Vascular Research Group are the Molecular Biology Group specialized in generating broader and selected toxin libraries, and the Cell Biology Group conducts further effectivity studies to narrow the group of candidate molecules on cellular systems, including immunological measurements in small animal models.